Piramal’s Buyout Of Minrad May Dent Strongholds Of Abbott, Baxter
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Abbott and Baxter are set to face strong competition in their traditional businesses of hospital anesthetic gas products as India's Piramal Healthcare has announced its acquisition of U.S. based Minrad International, a provider of generic inhalation anesthetics that include isoflurane, enflurane and sevoflurane. In addition, Minrad has filed an abbreviated new drug application for desflurane with U.S. FDA
You may also be interested in...
Piramal Close To Buying Local Critical Care Brands With An Eye On Global Markets
MUMBAI - Indian drug maker Piramal Healthcare's ambition to grow into a world player in hospital and critical care products is set to cross another milestone with the likely acquisition of a few brands in the anesthesia segment from an unlisted Indian pharmaceutical company
Piramal Close To Buying Local Critical Care Brands With An Eye On Global Markets
MUMBAI - Indian drug maker Piramal Healthcare's ambition to grow into a world player in hospital and critical care products is set to cross another milestone with the likely acquisition of a few brands in the anesthesia segment from an unlisted Indian pharmaceutical company
Piramal Close To Buying Local Critical Care Brands As Part Of A Global Strategy
Indian drug maker is rumored close to acquiring key anesthesia brands to enlarge its product portfolio and enable it to reach developing markets with a more complete offering.